20.01
price down icon15.50%   -3.67
after-market アフターアワーズ: 20.00 -0.01 -0.05%
loading
前日終値:
$23.68
開ける:
$21.82
24時間の取引高:
3.01M
Relative Volume:
7.20
時価総額:
$1.85B
収益:
$14.09M
当期純損益:
$-176.94M
株価収益率:
-7.5079
EPS:
-2.6652
ネットキャッシュフロー:
$-141.24M
1週間 パフォーマンス:
-18.66%
1か月 パフォーマンス:
+3.89%
6か月 パフォーマンス:
+0.86%
1年 パフォーマンス:
+110.63%
1日の値動き範囲:
Value
$19.59
$22.44
1週間の範囲:
Value
$19.59
$25.32
52週間の値動き範囲:
Value
$8.90
$26.35

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name
名前
Newamsterdam Pharma Company Nv
Name
セクター
Healthcare (1193)
Name
電話
35 206 2971
Name
住所
GOOIMEER 2-35, NARRDEN
Name
職員
62
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
NAMS's Discussions on Twitter

NAMS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NAMS 20.01 1.85B 14.09M -176.94M -141.24M -2.6652
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-01-18 開始されました Guggenheim Buy
2024-01-16 開始されました Piper Sandler Overweight
2023-10-30 開始されました RBC Capital Mkts Outperform

Newamsterdam Pharma Company Nv (NAMS) 最新ニュース

pulisher
Nov 20, 2024

Newamsterdam’s obicetrapib combo nails phase III LDL-C endpoints - BioWorld Online

Nov 20, 2024
pulisher
Nov 20, 2024

NewAmsterdam Pharma stock falls on trial data (NAMS:NASDAQ) - Seeking Alpha

Nov 20, 2024
pulisher
Nov 20, 2024

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH - The Manila Times

Nov 20, 2024
pulisher
Nov 19, 2024

NewAmsterdam Pharma stock holds Overweight rating with catalysts ahead in Ph3 topline readouts - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Trend Tracker for (NAMSW) - Stock Traders Daily

Nov 19, 2024
pulisher
Nov 19, 2024

Frazier Life Sciences Bolsters Leadership with Two Senior Industry Veterans | NAMS Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 18, 2024

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - The Manila Times

Nov 18, 2024
pulisher
Nov 15, 2024

RA Capital Management, L.P. Expands Stake in NewAmsterdam Pharma Co NV - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

GSA Capital Partners LLP Has $1.10 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) surges 13%; private equity firms who own 46% shares profited along with institutions - Simply Wall St

Nov 14, 2024
pulisher
Nov 13, 2024

When the Price of (NAMS) Talks, People Listen - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

Is NewAmsterdam Pharma (NAMS) Top Performing European Stock Heading into 2025? - Insider Monkey

Nov 13, 2024
pulisher
Nov 12, 2024

10 Top Performing European Stocks Heading into 2025 - Insider Monkey

Nov 12, 2024
pulisher
Nov 12, 2024

Lisanti Capital Growth LLC Invests $700,000 in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 12, 2024
pulisher
Nov 11, 2024

NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

Q4 EPS Forecast for NewAmsterdam Pharma Reduced by Analyst - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

William Blair Issues Pessimistic Forecast for NAMS Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Leerink Partnrs Has Bullish Outlook for NAMS FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Equities Analysts Offer Predictions for NAMS FY2024 Earnings - Defense World

Nov 11, 2024
pulisher
Nov 10, 2024

Leerink Partnrs Has Strong Estimate for NAMS FY2028 Earnings - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $33.80 - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

(NAMSW) Proactive Strategies - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 08, 2024

What is Leerink Partnrs' Forecast for NAMS FY2028 Earnings? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

NewAmsterdam Pharma Reports Strong Q3 and Trial Progress - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends - TipRanks

Nov 07, 2024
pulisher
Nov 06, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.80 Consensus PT from Analysts - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

NewAmsterdam Pharma Revenue Soars 900%, Reports Strong Q3 Results Ahead of Key Trial Data | NAMS Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

abrdn plc Purchases 53,060 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Nov 05, 2024
pulisher
Nov 03, 2024

(NAMS) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 01, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024
pulisher
Oct 29, 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - The Manila Times

Oct 29, 2024
pulisher
Oct 25, 2024

Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

Oct 25, 2024
pulisher
Oct 19, 2024

NewAmsterdam Pharma to Restate Prior Financials - Investing.com India

Oct 19, 2024
pulisher
Oct 18, 2024

NewAmsterdam Pharma to Restate Prior Financials By Investing.com - Investing.com Australia

Oct 18, 2024
pulisher
Oct 17, 2024

(NAMSW) Trading Report - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 14, 2024

NewAmsterdam Pharma Breaks Above 200-Day Moving AverageBullish for NAMS - Nasdaq

Oct 14, 2024
pulisher
Oct 12, 2024

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.80 - MarketBeat

Oct 12, 2024
pulisher
Oct 11, 2024

NewAmsterdam Pharma Company N.V. (NAMS) Price Target Increased by 8.93% to 31.11 - MSN

Oct 11, 2024
pulisher
Oct 11, 2024

Marshall Wace LLP Decreases Stake in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Oct 11, 2024
pulisher
Oct 07, 2024

When the Price of (NAMSW) Talks, People Listen - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 05, 2024

Millennium Management LLC Has $22.39 Million Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies - Seeking Alpha

Oct 04, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma executive sells shares worth $707,400 - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma executive sells shares worth $707,400 By Investing.com - Investing.com UK

Oct 01, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $16.60 - MarketBeat

Oct 01, 2024
pulisher
Oct 01, 2024

NewAmsterdam Pharma Company NV (NAMS) rating initates by TD Cowen - Knox Daily

Oct 01, 2024
pulisher
Oct 01, 2024

Does NewAmsterdam Pharma Company NV (NAMS) offer a good opportunity for investors? - SETE News

Oct 01, 2024
pulisher
Sep 30, 2024

Newamsterdam Pharma exec buys $17,332 in company stock By Investing.com - Investing.com Australia

Sep 30, 2024
pulisher
Sep 30, 2024

Newamsterdam Pharma exec buys $17,332 in company stock - Investing.com India

Sep 30, 2024

Newamsterdam Pharma Company Nv (NAMS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
大文字化:     |  ボリューム (24 時間):